In a Sept. 28 statement, CVS said it made the decision “out of an abundance of caution.”
The decision to freeze sales of the drug comes as the FDA is evaluating whether small amounts of the carcinogen, N-nitrosodimethylamine, pose a risk to patients.
To date, no recall has been issued on Sanofi’s brand-name drug Zantac.
Customers who bought Zantac at CVS can return it for a refund.
Read the full article here.
More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.